Author: admin

“Delveinsight Business Research LLP”

DelveInsight’s “Hyperkalaemia Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Hyperkalaemia market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Hyperkalaemia drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Hyperkalaemia treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Hyperkalaemia: An Overview

Hyperkalemia is defined as a high potassium level in the blood. Potassium helps in the proper functioning of nerves and muscles, including the heart, but too much potassium in the blood can be dangerous and can cause serious heart problems and sudden death.

Hyperkalemia is defined as a serum potassium concentration that is equal to or greater than 5.5 mEq/L from a non-hemolyzed whole blood sample. The normal potassium level in the blood is 3.5-5.0 mEq/L. Furthermore, it can be classified according to serum potassium into mild (5.5–6.5 mmol/L), moderate (6.5–7.5 mmol/L) and severe (>7.5 mmol/L) hyperkalemia. Often hyperkalemia is asymptomatic, but at times they are often nonspecific such as heart palpitations, nausea, weakness, or paresthesia. Common acute manifestations of significant hyperkalemia include muscle weakness and ECG changes, with the latter having the potential to progress to a life-threatening arrhythmia.

Risk factors for hyperkalemia include several conditions such as chronic kidney disease, diabetes, congestive heart failure, and certain medications that disrupt the potassium balance. Also, males are found to suffer more than females with Hyperkalemia.

Hyperkalaemia Market Key Facts

• In 2021, the total diagnosed prevalent cases of Hyperkalemia were estimated to be approximately 5,517,000+ cases in the 7MM. These cases are expected to increase by 2032 at a CAGR of 2.8% during the study period (2019–2032).

• Among the 7MM, the United States accounted for nearly 79% of the total diagnosed prevalent cases of Hyperkalemia in the 7MM in the year 2021 which is expected to increase further by 2032.

• Among EU4 and the United Kingdom, Germany had the highest total diagnosed prevalent cases of Hyperkalemia with approximately 212,445 cases in 2021, while Spain had the lowest diagnosed prevalent population of Hyperkalemia with approximately 15,918 cases in 2021.

• According to the study conducted by Kashihara et al. (2019) titled “Hyperkalemia in Real-World Patients under Continuous Medical Care in Japan,” hyperkalemia prevalence was 67.9/1,000 and increased in patients with chronic kidney disease (CKD), heart failure, and renin-angiotensin-aldosterone system inhibitor (RAASi) use. The mean age was found to be 72.4±13.0 years, and 55% were men.

Hyperkalaemia Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Hyperkalaemia pipeline therapies. It also thoroughly assesses the Hyperkalaemia market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete details of the market trend for each marketed Hyperkalaemia drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Hyperkalaemia Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted Hyperkalaemia epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Hyperkalaemia epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the Hyperkalaemia Epidemiology, Segmented as –

• Prevalent cases of Hyperkalemia

• Gender-specific prevalent cases of Hyperkalemia

• Severity-specific prevalent cases of Hyperkalemia [Mild, Moderate, and Severe]

• Prevalent cases of Hyperkalemia with associated risk factors (Chronic kidney disease (CKD), heart failure, diabetes, hypertension, and others)

• Diagnosed and treatable cases of Hyperkalemia

Hyperkalaemia Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Hyperkalaemia market or expected to be launched during the study period. The analysis covers the Hyperkalaemia market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Hyperkalaemia drugs based on their sale and market share.

The report also covers the Hyperkalaemia pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Hyperkalaemia companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Hyperkalaemia Market Will Evolve and Grow by 2032 @ 

https://www.delveinsight.com/sample-request/hyperkalemia-market

Hyperkalaemia Therapeutics Analysis

The treatment of hyperkalemia is directly related to the swiftness with which hyperkalemia has developed in an individual with the absolute level of hyperkalemia and the evidence of toxicity. The faster the potassium rises, the higher the level is, and the stronger will be the evidence of cardiotoxicity, resulting in the requirement for more aggressive therapy.

However, frequently used therapies for hyperkalemia may also be associated with morbidity. Therapeutics may include the simultaneous administration of insulin and glucose (associated with frequent dysglycemic complications), β-2 agonists (associated with potential cardiac ischemia and arrhythmias), hypertonic sodium bicarbonate infusion in the acidotic patient (representing a large hypertonic sodium load) and renal replacement therapy (effective but invasive). In addition, potassium-lowering drugs can cause a rapid decrease in serum potassium levels, leading to cardiac hyperexcitability and rhythm disorders. 

To further improve the treatment outlook, several major pharma and biotech companies are actively working in the Hyperkalaemia Therapeutics Market.

Hyperkalaemia Companies Actively Working in the Therapeutics Market Include

• AstraZeneca

• Ardelyx

• Vifor Pharma

• Zeria Pharmaceutical

And Many Others

Emerging and Marketed Hyperkalaemia Therapies Covered in the Report Include:

• RDX013: Ardelyx

• ZG-801/Patiromer (Zeria)

And Many More

Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @

https://www.delveinsight.com/sample-request/hyperkalemia-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Hyperkalaemia Competitive Intelligence Analysis

4. Hyperkalaemia Market Overview at a Glance

5. Hyperkalaemia Disease Background and Overview

6. Hyperkalaemia Patient Journey

7. Hyperkalaemia Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Hyperkalaemia Treatment Algorithm, Current Treatment, and Medical Practices

9. Hyperkalaemia Unmet Needs

10. Key Endpoints of Hyperkalaemia Treatment

11. Hyperkalaemia Marketed Therapies

12. Hyperkalaemia Emerging Drugs and Latest Therapeutic Advances

13. Hyperkalaemia Seven Major Market Analysis

14. Attribute Analysis

15. Hyperkalaemia Market Outlook (In US, EU5, and Japan)

16. Hyperkalaemia Companies Active in the Market

17. Hyperkalaemia Access and Reimbursement Overview

18. KOL Views on the Hyperkalaemia Market

19. Hyperkalaemia Market Drivers

20. Hyperkalaemia Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Request the Sample PDF to Learn More About the Key Offerings of the Report @

https://www.delveinsight.com/sample-request/hyperkalemia-market

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports by DelveInsight

Optic Neuritis Market

“Optic Neuritis Market Insights, Epidemiology, and Market Forecast-2032” report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the Optic Neuritis market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Optic Neuritis market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/medical-devices

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Hyperkalaemia Market Gearing Up for Outstanding Expansion During the Forecast Period (2023-32) | AstraZeneca, Ardelyx, Vifor Pharma, Zeria Pharmaceutical

“Delveinsight Business Research LLP”

DelveInsight’s “Non-Hodgkin’s Lymphoma Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Non-Hodgkin’s Lymphoma market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Non-Hodgkin’s Lymphoma drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Non-Hodgkin’s Lymphoma treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Non-Hodgkin’s Lymphoma: An Overview

Non-Hodgkin lymphoma is a type of cancer that generally develops in the lymph nodes and lymphatic tissue found in organs such as the stomach, intestines, or skin. In some cases, NHL involves bone marrow and blood. NHL is not just one disease–it’s actually a diverse group of blood cancers that all arise from lymphocytes (white blood cells that are part of the immune system). Lymphoma cells may develop in just one place or in many sites in the body. NHL has many different subtypes, which are either indolent (slow-growing) or aggressive (fast-growing).

Non-Hodgkin lymphoma is divided into more than 30 types, classified based on the type of lymphocyte involved: B lymphocytes (B cells) or T lymphocytes (T cells). Non-Hodgkin lymphoma is further classified by other factors, including whether it is aggressive (fast-growing) or indolent (slow-growing).

As per the American Cancer Society (2022), NHL is one of the most common cancers in the United States, accounting for about 4% of all cancers. About 80,400+ people are anticipated to be diagnosed with NHL in 2022.

Non-Hodgkin’s Lymphoma Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Non-Hodgkin’s Lymphoma pipeline therapies. It also thoroughly assesses the Non-Hodgkin’s Lymphoma market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete details of the market trend for each marketed Non-Hodgkin’s Lymphoma drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Non-Hodgkin’s Lymphoma Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted Non-Hodgkin’s Lymphoma epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Non-Hodgkin’s Lymphoma epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the Non-Hodgkin’s Lymphoma Epidemiology, Segmented as –

• Total Incident Cases of Non-Hodgkin’s Lymphoma 

• Type-specific Incident Cases of Non-Hodgkin’s Lymphoma

• Stage-specific Incident Cases of Non-Hodgkin’s Lymphoma

• Age-specific Incident Cases of Non-Hodgkin’s Lymphoma

• Treatable Cases of Non-Hodgkin’s Lymphoma by Line of Therapies

Non-Hodgkin’s Lymphoma Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Non-Hodgkin’s Lymphoma market or expected to be launched during the study period. The analysis covers the Non-Hodgkin’s Lymphoma market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Non-Hodgkin’s Lymphoma drugs based on their sale and market share.

The report also covers the Non-Hodgkin’s Lymphoma pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Non-Hodgkin’s Lymphoma companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Non-Hodgkin’s Lymphoma Market Will Evolve and Grow by 2032 @ 

https://www.delveinsight.com/sample-request/non-hodgkins-lymphoma-nhl-market

Non-Hodgkin’s Lymphoma Therapeutics Analysis

The treatment of non-Hodgkin’s Lymphoma depends upon the severity and spread rate of the disease. Various types of treatment regimens are used to treat NHL, such as chemotherapy and other drug therapy, radiation therapy (usually combined with chemotherapy), stem cell transplantation, and watch-and-wait. If the patient does not respond to these, targeted therapies are used. To further improve the treatment scenario, globally, several key companies are actively working in the Non-Hodgkin’s Lymphoma Therapeutics Market.

Non-Hodgkin’s Lymphoma Companies Actively Working in the Therapeutics Market Include

• AbbVie

• Angiocrine Bioscience

• Artiva Biotherapeutics

• AstraZeneca

• Autolus

• Genmab

• Jiangsu Hengrui Medicine

• Loxo Oncology

• Novartis

• Pacylex Pharmaceuticals

• Zentera Therapeutics

Many Others

Emerging and Marketed Non-Hodgkin’s Lymphoma Therapies Covered in the Report Include:

• ZN-d5: Zentera Therapeutics

• PCLX-001: Pacylex Pharmaceuticals

• LOXO-305: Loxo Oncology

• Capivasertib: AstraZeneca

• AB-101: Artiva Biotherapeutics

• AUTO4: Autolus

• Tisagenlecleucel: Novartis

• AB-205: Angiocrine Bioscience

And Many Others

Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @

https://www.delveinsight.com/sample-request/non-hodgkins-lymphoma-nhl-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Non-Hodgkin’s Lymphoma Competitive Intelligence Analysis

4. Non-Hodgkin’s Lymphoma Market Overview at a Glance

5. Non-Hodgkin’s Lymphoma Disease Background and Overview

6. Non-Hodgkin’s Lymphoma Patient Journey

7. Non-Hodgkin’s Lymphoma Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Non-Hodgkin’s Lymphoma Treatment Algorithm, Current Treatment, and Medical Practices

9. Non-Hodgkin’s Lymphoma Unmet Needs

10. Key Endpoints of Non-Hodgkin’s Lymphoma Treatment

11. Non-Hodgkin’s Lymphoma Marketed Therapies

12. Non-Hodgkin’s Lymphoma Emerging Drugs and Latest Therapeutic Advances

13. Non-Hodgkin’s Lymphoma Seven Major Market Analysis

14. Attribute Analysis

15. Non-Hodgkin’s Lymphoma Market Outlook (In US, EU5, and Japan)

16. Non-Hodgkin’s Lymphoma Companies Active in the Market

17. Non-Hodgkin’s Lymphoma Access and Reimbursement Overview

18. KOL Views on the Non-Hodgkin’s Lymphoma Market

19. Non-Hodgkin’s Lymphoma Market Drivers

20. Non-Hodgkin’s Lymphoma Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Request the Sample PDF to Learn More About the Key Offerings of the Report @

https://www.delveinsight.com/sample-request/non-hodgkins-lymphoma-nhl-market

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports by DelveInsight

Scleritis Market

“Scleritis Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Scleritis market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Scleritis market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/oncology

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Non-Hodgkin\’s Lymphoma Market Poised for Extraordinary Growth During the Forecast Period (2023-32), Asserts DelveInsight | AbbVie, Angiocrine, AstraZeneca, Autolus, Genmab, Loxo Oncology, Novartis

“Delveinsight Business Research LLP”

DelveInsight’s “Osteoporosis Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Osteoporosis market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Osteoporosis drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Osteoporosis treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Osteoporosis: An Overview

Osteoporosis is defined as a systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue, with a consequent increase in bone fragility and susceptibility to fracture. This well-established definition, developed by the international consensus in 1993, captures two important characteristics of the disease: its adverse effects on bone mass and microstructure, and the clinical outcome of fracture.

It is a condition that often remains undiagnosed until it manifests as a low-trauma fracture of the hip, spine, proximal humerus, pelvis, and/or wrist, which frequently leads to hospitalization. Estrogen is considered important in maintaining bone density in women. When estrogen levels drop after menopause, loss of bone density accelerates. During the first 5 to 10 years after menopause, women can suffer up to 2-4% loss of bone density per year.

The causes of osteoporosis include hyperparathyroidism, hyperglycemia, medications, smoking, alcohol use, oxidative stress, inflammation, calcium deficiency, menopause, etc. The most common symptom of osteoporosis is a vertebral compression fracture or hip fracture. The compression fractures in the spine, caused by weakened vertebrae can lead to pain in the mid-back area. The fractures often stabilize on their own, and the pain goes away, but sometimes the pain persists because the crushed bone continues to move around and break. The symptoms include loss of height, back pain, increased number of bed days, depression, etc.

The key risk factors for osteoporosis include genetics, lack of exercise, lack of calcium and vitamin D, personal history of fracture as an adult, cigarette smoking, excessive alcohol consumption, history of rheumatoid arthritis, low body weight, and family history of osteoporosis.

Osteoporosis Market Key Facts

• According to the CDC, in the US, the prevalence of low bone mass, a precursor of Osteoporosis, at either the femur neck or lumbar spine or both among adults aged 50 and over was 43.1% and was higher among women (51.5%) compared with men (33.5%). Osteoporosis prevalence increased from 2007–2008 to 2017–2018 among women, but not men.

• According to the International Osteoporosis Foundation, in the UK, the prevalence of Osteoporosis in the total population amounted to 5.2%, on par with the EU27+2 average (5.6%). In the UK, 21.9% of women and 6.7% of men aged 50 years or more were estimated to have Osteoporosis. Hip fracture is the most serious consequence of Osteoporosis in terms of morbidity, mortality, and health care expenditure.

• According to a study conducted by Bolster et al. titled “Osteoporosis” states that about 8 million women and 2 million men in the United States have osteoporosis. In addition, more than 95% of women and about 80% of men are primary osteoporosis. Whereas, secondary osteoporosis is less than 5% in women and about 20% in men.

• DARBA et al. conducted a study titled “Cost-utility of denosumab for the treatment of postmenopausal osteoporosis in Spain,” which found the prevalence rate of postmenopausal osteoporosis (PMO) of approximately 25% for women aged 60–69 years and 40% for those aged 70–79 years was in Spain.

Osteoporosis Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Osteoporosis pipeline therapies. It also thoroughly assesses the Osteoporosis market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete details of the market trend for each marketed Osteoporosis drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Osteoporosis Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted Osteoporosis epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Osteoporosis epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the Osteoporosis Epidemiology, Segmented as –

• Prevalence of Osteoporosis

• Prevalence of Primary Osteoporosis

• Prevalence of Secondary Osteoporosis 

• Incidence of Osteoporotic Fractures

• Diagnosed Prevalence of Osteoporosis

• Gender-specific Prevalence of Osteoporosis

• Osteoporosis-related comorbidities

Osteoporosis Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Osteoporosis market or expected to be launched during the study period. The analysis covers the Osteoporosis market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Osteoporosis drugs based on their sale and market share.

The report also covers the Osteoporosis pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Osteoporosis companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Osteoporosis Market Will Evolve and Grow by 2032 @ 

https://www.delveinsight.com/sample-request/osteoporosis-market

Osteoporosis Therapeutics Analysis

The treatment of osteoporosis involves treating and preventing fractures and using medicines to strengthen the weak bones. According to the International Osteoporosis Foundation, for patients at high risk, drug treatments are needed to effectively reduce the risk of broken bones due to osteoporosis. Treatments have been shown to reduce the risk of hip fracture by up to 40%, vertebral fractures by 30-70%, and, with some medications, reduce the risk of non-vertebral fractures by 15-20%.

The treatment landscape of osteoporosis comprises mostly pharmacological therapies, which is further characterized as anti-resorptive agents (i.e., bisphosphonates, estrogen agonist/antagonists (EAAs), estrogens, calcitonin, and denosumab), anabolic agents (i.e., teriparatide and abaloparatide), and mixed agents (i.e., Romosozumab). Apart from the mentioned pharmacotherapies, there are several other anti-resorptive treatment options to treat osteoporosis, such as estrogen replacement and selective estrogen receptor modulators, which further comprise of raloxifene, lasofoxifene, and bazedoxifene. In addition, a few dietary supplements such as calcium and vitamin D also provide benefits to patients with osteoporosis.

To further improve the treatment outlook, several major pharma and biotech companies are developing therapies for Osteoporosis. Currently, Celltrion is leading the therapeutics Osteoporosis drug candidates in the most advanced stage of clinical development.

Osteoporosis Companies Actively Working in the Therapeutics Market Include

• Shanghai JMT-Bio Inc.

• Transcenta Holding

• Celltrion

• Sandoz

• Enzene Biosciences

• Fresenius Kabi

• Gedeon Richter

• Samsung Bioepis

• Alvotech

• MAbxience

• Shanghai Henlius Biotech

And Many Others

Emerging and Marketed Osteoporosis Therapies Covered in the Report Include:

• JMT 103: Shanghai JMT-Bio Inc.

• TST-002: Transcenta Holding

• CT-P41: Celltrion

And Many More

Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @

https://www.delveinsight.com/sample-request/osteoporosis-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Osteoporosis Competitive Intelligence Analysis

4. Osteoporosis Market Overview at a Glance

5. Osteoporosis Disease Background and Overview

6. Osteoporosis Patient Journey

7. Osteoporosis Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Osteoporosis Treatment Algorithm, Current Treatment, and Medical Practices

9. Osteoporosis Unmet Needs

10. Key Endpoints of Osteoporosis Treatment

11. Osteoporosis Marketed Therapies

12. Osteoporosis Emerging Drugs and Latest Therapeutic Advances

13. Osteoporosis Seven Major Market Analysis

14. Attribute Analysis

15. Osteoporosis Market Outlook (In US, EU5, and Japan)

16. Osteoporosis Companies Active in the Market

17. Osteoporosis Access and Reimbursement Overview

18. KOL Views on the Osteoporosis Market

19. Osteoporosis Market Drivers

20. Osteoporosis Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Request the Sample PDF to Learn More About the Key Offerings of the Report @

https://www.delveinsight.com/sample-request/osteoporosis-market

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports by DelveInsight

Hypereosinophilic Syndrome Market

“Hypereosinophilic Syndrome Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Hypereosinophilic Syndrome market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Hypereosinophilic Syndrome market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/market-research

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Osteoporosis Market Poised for Phenomenal Expansion During the Forecast Period (2023-32) – Estimates DelveInsight | Transcenta Holding, Celltrion, Sandoz, Samsung Bioepis, Alvotech, MAbxience

“Delveinsight Business Research LLP”

The high-grade NMIBC pipeline possesses potential drugs in mid and late-stage developments to be launched in the near future. The major key players include Urogen Pharma, Pfizer, Roche, CG Oncology, ImmunityBio, Theralase, enGene, and others that hold the potential to create a significant positive shift in NMIBC in the market size and the treatment scenario.

DelveInsight’s “Non-Muscle Invasive Bladder Cancer (NMIBC) Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Non-Muscle Invasive Bladder Cancer market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Non-Muscle Invasive Bladder Cancer drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Non-Muscle Invasive Bladder Cancer treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Non-Muscle Invasive Bladder Cancer (NMIBC): An Overview

Non-muscle invasive bladder cancer (NMIBC) is cancer of the bladder. NMIBC is a cancer that grows only in the thin tissue on the inside surface of the bladder. With NMIBC, the bladder muscle is not involved, and the tumor does not spread outside the bladder.

There are a number of things that may increase the risk of getting bladder cancer including smoking, working in places that make plastics, paints, leather, and rubber, cancer drugs, radiation to the pelvis, and genes. Blood in the urine is the most common symptom of bladder cancer, which is often painless. Other symptoms of NMIBC include frequent and urgent urination, pain when you pass urine, pain in your lower abdomen, and back pain.

The best treatment for NMIBC is early diagnosis and early care. Treatment will also depend on the stage and the growth of cancer. Treatments for non-muscle invasive bladder cancer include cystoscopic transurethral resection of the bladder tumor (TURBT), intravesical therapy, and surgery. If these options fail to treat the cancer, your doctor may recommend removing the complete bladder.

FDA has approved many drugs for the treatment of bladder cancer but to date there are only two drugs which are being given for the treatment of NMIBC which include KEYTRUDA and ADSTILADRIN, approved in 2020 and 2022, respectively.

Non-Muscle Invasive Bladder Cancer Market Key Facts

• The total prevalent cases of Bladder Cancer in the US were approximately 800,000 cases in 2022.

• As per DelveInsight’s estimates, in the US, low-risk NMIBC patients were higher as compared to the high-risk NMIBC patients in 2022.

• EU4 and the UK had the highest number of diagnosed prevalent cases of NMIBC among the 7MM. In 2022, EU4 and the UK accounted for approximately 250,000 cases.

• Age-specific incidence of NMIBC cancer increased from 5.52 to 9.09 per 100,000 from 1998 to 2006, as reported in a population-based study on the US population (Nelisen et al., al 2014)

• Bladder Cancer is more common in males than females.

• In 2022, total tumor stage-specific diagnosed prevalent cases of NMIBC in Japan for stages Ta, Tis, and T1 were around 50,000, 2,543, and 25,000, respectively.

Non-Muscle Invasive Bladder Cancer (NMIBC) Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Non-Muscle Invasive Bladder Cancer pipeline therapies. It also thoroughly assesses the Non-Muscle Invasive Bladder Cancer market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete details of the market trend for each marketed Non-Muscle Invasive Bladder Cancer drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Non-Muscle Invasive Bladder Cancer (NMIBC) Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted Non-Muscle Invasive Bladder Cancer epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Non-Muscle Invasive Bladder Cancer epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the Non-Muscle Invasive Bladder Cancer Epidemiology, Segmented as –

• Prevalent cases of Bladder Cancer in the 7MM (2019-2032)

• Age-specific Diagnosed Prevalence of NMIBC in the 7MM (2019-2032)

• Diagnosed Prevalent cases of NMIBC in the 7MM (2019-2032)

• Tumor stage-specific Diagnosed Prevalence of NMIBC in the 7MM (2019-2032)

• Risk-specific Diagnosed Prevalence of NMIBC in the 7MM (2019-2032)

• Grade-specific Diagnosed Prevalence of NMIBC in the 7MM (2019-2032)

Non-Muscle Invasive Bladder Cancer (NMIBC) Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Non-Muscle Invasive Bladder Cancer market or expected to be launched during the study period. The analysis covers the Non-Muscle Invasive Bladder Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Non-Muscle Invasive Bladder Cancer drugs based on their sale and market share.

The report also covers the Non-Muscle Invasive Bladder Cancer pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Non-Muscle Invasive Bladder Cancer companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Non-Muscle Invasive Bladder Cancer Market Will Evolve and Grow by 2032 @ 

https://www.delveinsight.com/sample-request/non-muscle-invasive-bladder-cancer-market

Non-Muscle Invasive Bladder Cancer (NMIBC) Therapeutics Analysis

NMIBC remains a very challenging disease to treat, with high rates of recurrence and progression associated with current therapies. The high rates of progression and recurrence with current therapies for NMIBC necessitate lifelong active surveillance, making bladder cancer the most expensive cancer to treat from diagnosis to death, as well as driving the need for the development of new therapies in patients with NMIBC.

The current treatment regimen includes KEYTRUDA (pembrolizumab), ADSTILADRIN, surgery, intravesical immunotherapy (BCG), and intravesical chemotherapy. Intermediate- or high-risk NMIBC is generally treated with transurethral resection of bladder tumor (TURBT), followed by adjuvant BCG immunotherapy which is the gold standard treatment for reducing tumor recurrence rates and preventing subsequent stage progression. Stage 0 bladder cancer is most often treated with TURBT with fulguration followed by intravesical therapy within 24 h. Sometimes no further treatment is needed. Cystoscopy is then done every 3–6 months to watch for signs that cancer has come back. Valrubicin might be used if BCG stops working. However, not all experts agree on this treatment.

Several major pharma and biotech giants are developing therapies for Non-Muscle Invasive Bladder Cancer. Currently, UroGen Pharma is leading the therapeutics market with its Non-Muscle Invasive Bladder Cancer drug candidates in the most advanced stage of clinical development.

In December 2022, US FDA approved ADSTILADRIN (nadofaragene firadenovec-vncg), a non-replicating adenoviral vector-based gene therapy indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors.

Non-Muscle Invasive Bladder Cancer (NMIBC) Companies Actively Working in the Therapeutics Market Include

Abraxis Bioscience, Asieris Pharmaceuticals, AstraZeneca, CG Oncolgy, Hamlet Pharma, ImmunityBio, Incyte Corporation, Janssen Pharmaceuticals, LIPAC Oncology, Prokarium, Rapamycin Holdings, Sasanlimab, Sesen Bio, Taizhou Hanzhong biomedical, Theralase Technologies, Vaxiion Therapeutics, Viralytics, UroGen Pharma, and many more.

Emerging and Marketed Non-Muscle Invasive Bladder Cancer (NMIBC) Therapies Covered in the Report Include:

Adstiladrin(nadofaragenefiradenovec/Syn3): FKD Therapies Oy/Ferring Pharmaceuticals, APL-1202: Asieris Pharmaceuticals, CG0070: CG Oncology, EG-70: enGene, Erdafitinib: Janssen Pharmaceuticals, Keytruda: Merck, N-803 (ALT-803): ImmunityBio/Altor Biosciences, PF-06801591: Pfizer, Sasanlimab (PF-06801591): Pfizer, TARA-002: Protara Therapeutics, TECENTRIQ: Roche, TL-532: Tollys, TLD 1433: Theralase Technologies, UGN-102: UroGen Pharma, VAX 014: Vaxiion Therapeutics, Vicinium: Viventia Bio/Sesen Bio, KEYTRUDA (pembrolizumab): MSD, ADSTILADRIN (nadofaragene firadenovec-vncg): Ferring Pharmaceuticals, and many more.

Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @

https://www.delveinsight.com/sample-request/non-muscle-invasive-bladder-cancer-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Non-Muscle Invasive Bladder Cancer Competitive Intelligence Analysis

4. Non-Muscle Invasive Bladder Cancer Market Overview at a Glance

5. Non-Muscle Invasive Bladder Cancer Disease Background and Overview

6. Non-Muscle Invasive Bladder Cancer Patient Journey

7. Non-Muscle Invasive Bladder Cancer Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Non-Muscle Invasive Bladder Cancer Treatment Algorithm, Current Treatment, and Medical Practices

9. Non-Muscle Invasive Bladder Cancer Unmet Needs

10. Key Endpoints of Non-Muscle Invasive Bladder Cancer Treatment

11. Non-Muscle Invasive Bladder Cancer Marketed Therapies

12. Non-Muscle Invasive Bladder Cancer Emerging Drugs and Latest Therapeutic Advances

13. Non-Muscle Invasive Bladder Cancer Seven Major Market Analysis

14. Attribute Analysis

15. Non-Muscle Invasive Bladder Cancer Market Outlook (In US, EU5, and Japan)

16. Non-Muscle Invasive Bladder Cancer Companies Active in the Market

17. Non-Muscle Invasive Bladder Cancer Access and Reimbursement Overview

18. KOL Views on the Non-Muscle Invasive Bladder Cancer Market

19. Non-Muscle Invasive Bladder Cancer Market Drivers

20. Non-Muscle Invasive Bladder Cancer Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Request the Sample PDF to Learn More About the Key Offerings of the Report @

https://www.delveinsight.com/sample-request/non-muscle-invasive-bladder-cancer-market

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports by DelveInsight

Graves Orbitopathy Market

“Graves Orbitopathy Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Graves Orbitopathy market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Graves Orbitopathy market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/oncology

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Non-Muscle Invasive Bladder Cancer (NMIBC) Market: Latest Study by DelveInsight Reveals a Lucrative Investment Opportunity and Growth Prospect | Abraxis, Asieris, AstraZeneca, CG Oncolgy, ImmunityBio

“Delveinsight Business Research LLP”

DelveInsight’s “Multiple Sclerosis Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Multiple Sclerosis market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Multiple Sclerosis drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Multiple Sclerosis treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Multiple Sclerosis: An Overview

Multiple Sclerosis (MS) is an unpredictable, autoimmune disease that affects the central nervous system. In Multiple Sclerosis, the body’s own immune system produces cells, and proteins (antibodies) to attack the fatty substance, myelin, which is responsible for protecting the nerve fibers. This is often characterized by relapsing episodes of neurologic impairment followed by remissions.

The damaged myelin forms scar tissue (sclerosis). Often the nerve fiber is also damaged. When any part of the myelin sheath or nerve fiber is damaged or destroyed, nerve impulses traveling to and from the brain and spinal cord are distorted or interrupted. People with Multiple Sclerosis generally develop symptoms in their late 20s, experiencing visual and sensory disturbances, limb weakness, gait problems, and bladder and bowel syndromes. Initially, they may have partial recovery, but over time they develop progressive disability.

Multiple Sclerosis-affected individuals may experience a variety of symptoms, physically, emotionally, mentally, and psychologically. The severity and types of symptoms differ among individuals; thus, symptoms differ among different people.

With the continuous efforts in research and development, various companies are developing therapies, NeuroVax (Immune Response BioPharma), CNM-Au8 (Clene Nanomedicine), Tolebrutinib (SAR442168) (Sanofi), Evobrutinib/M2951 (Merck Healthcare KGaA), and many others are expected to enter the 7MM market by 2032.

Multiple Sclerosis Market Key Facts

• The market size of Multiple Sclerosis in the seven major markets was found to be USD 22,381 million in 2020.

• The total 7MM prevalent cases of Multiple Sclerosis in 2022 were approximately 1,275,800 cases. The cases are expected to increase by 2032.

• The prevalent cases of Multiple Sclerosis in the United States were found to be approximately 723,500 cases.

• Among EU-5 countries, Germany had the highest number of prevalent cases of Multiple Sclerosis, which were approximately 211,601 cases in 2021. As per DelveInsight’s analysis, this will increase by 2032. On the other hand, the prevalent population of Multiple Sclerosis in Spain was found to be approximately 45,425 cases which as per DelveInsight’s analysis was the lowest in EU-5.

Multiple Sclerosis Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Multiple Sclerosis pipeline therapies. It also thoroughly assesses the Multiple Sclerosis market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete details of the market trend for each marketed Multiple Sclerosis drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Multiple Sclerosis Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted Multiple Sclerosis epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Multiple Sclerosis epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the Multiple Sclerosis Epidemiology, Segmented as –

• Total Prevalent Cases of Multiple Sclerosis in the 7MM [2019–2032]

• Prevalence of Multiple Sclerosis Based on Age in the 7MM [2019–2032]

• Prevalence of Multiple Sclerosis Based on Age in the 7MM [2019–2032]

• Phenotype-specific prevalent cases of Multiple Sclerosis in the 7MM [2019–2032]

• Extent of Disability (EDSS) in Multiple Sclerosis in the 7MM [2019–2032]

Multiple Sclerosis Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Multiple Sclerosis market or expected to be launched during the study period. The analysis covers the Multiple Sclerosis market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Multiple Sclerosis drugs based on their sale and market share.

The report also covers the Multiple Sclerosis pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Multiple Sclerosis companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Multiple Sclerosis Market Will Evolve and Grow by 2032 @ 

https://www.delveinsight.com/sample-request/multiple-sclerosis-market

Multiple Sclerosis Therapeutics Analysis

The Multiple Sclerosis treatment market looks promising as the market is emerging with newer acute treatments that have been designated by the FDA to treat Multiple Sclerosis. Several major pharma and biotech companies are developing therapies for Multiple sclerosis. Currently, TG Therapeutics is leading the therapeutics market with its Multiple sclerosis drug candidates in the most advanced stage of clinical development.

Multiple Sclerosis Companies Actively Working in the Therapeutics Market Include

TG Therapeutics, Immunic, Atara Biotherapeutics, ANOKION, ImStem Biotechnology, Merck Serono, CinnaGen, Immune Response BioPharma, Inc., Clene Nanomedicine, GeNeuro SA, Sanofi, Bristol-Myers Squibb, HuniLife Biotechnology, Inc., Emerald Health Pharmaceuticals, Biogen, RemeGen Co., Ltd., Antisense Therapeutics, Immune Response BioPharma, Biocad, AB Science, Genentech, Novartis, Pipeline Therapeutics, ASLAN Pharmaceuticals, GlaxoSmithKline, Lucid Psycheceuticals, Voronoi, Hanmi Pharmaceutical, Mapi Pharma, f5 Therapeutics, Autobahn Therapeutics, AstraZeneca, ZyVersa Therapeutics, RedHill Biopharma, Gossamer Bio, Sarepta Therapeutics, BrainStorm Cell Limited, CytoDyn, Pear Therapeutics, ABION, and many others.

Emerging and Marketed Multiple Sclerosis Therapies Covered in the Report Include:

• Ublituximab: TG Therapeutics

• IMU-838: Immunic

• ATA188: Atara Biotherapeutics

• ANK-700: ANOKION

• NeuroVax: Immune Response BioPharma Inc.

• CNM-Au8: Clene Nanomedicine

• Tolebrutinib (SAR442168): Sanofi

• Evobrutinib/M2951: Merck Healthcare KGaA

• Ublituximab: TG Therapeutics, Inc.

• ALKS 8700: Alkermes/Biogen

• Arbaclofen (Arbaclofen ER): Osmotica Pharmaceutical

And Many More

Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @

https://www.delveinsight.com/sample-request/multiple-sclerosis-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Multiple Sclerosis Competitive Intelligence Analysis

4. Multiple Sclerosis Market Overview at a Glance

5. Multiple Sclerosis Disease Background and Overview

6. Multiple Sclerosis Patient Journey

7. Multiple Sclerosis Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Multiple Sclerosis Treatment Algorithm, Current Treatment, and Medical Practices

9. Multiple Sclerosis Unmet Needs

10. Key Endpoints of Multiple Sclerosis Treatment

11. Multiple Sclerosis Marketed Therapies

12. Multiple Sclerosis Emerging Drugs and Latest Therapeutic Advances

13. Multiple Sclerosis Seven Major Market Analysis

14. Attribute Analysis

15. Multiple Sclerosis Market Outlook (In US, EU5, and Japan)

16. Multiple Sclerosis Companies Active in the Market

17. Multiple Sclerosis Access and Reimbursement Overview

18. KOL Views on the Multiple Sclerosis Market

19. Multiple Sclerosis Market Drivers

20. Multiple Sclerosis Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Request the Sample PDF to Learn More About the Key Offerings of the Report @

https://www.delveinsight.com/sample-request/multiple-sclerosis-market

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports by DelveInsight

Degenerative Disc Disease Market

“Degenerative Disc Disease Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Degenerative Disc Disease market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Degenerative Disc Disease market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/medical-devices

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Multiple Sclerosis Market: Latest Study by DelveInsight Forecasts Remarkable Growth During the Forecast Period (2023-32) | Immunic, ANOKION, Merck Serono, CinnaGen, GeNeuro, Sanofi, Biogen, RemeGen

“Delveinsight Business Research LLP”

DelveInsight’s “Burns Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Burns market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Burns drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Burns treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Burns: An Overview

Burn injuries are underappreciated injuries that are associated with substantial morbidity and mortality. Burn injuries, particularly severe burns, are accompanied by an immune and inflammatory response, metabolic changes, and distributive shock that can be challenging to manage and can lead to multiple organ failures. Of great importance is that the injury affects not only physical health but also the patient’s mental health and quality of life.

Burn injuries are underappreciated trauma that can affect anyone, anytime and anywhere. The injuries can be caused by friction, cold, heat, radiation, chemical, or electric sources, but most burn injuries are caused by heat from hot liquids, solids, or fire. Although all burn injuries involve tissue destruction due to energy transfer, different causes can be associated with different physiological and pathophysiological responses.

In addition to determining the cause of a burn injury, it is imperative to classify the injury according to its severity –its depth and size. Burns that affect the uppermost layer of the skin (epidermis only) are classed as superficial (first-degree) burns; the skin becomes red, and the pain experienced is limited in duration. Superficial partial-thickness (second-degree) burns (formerly known as 2A burns) are painful, weep, require dressing and wound care, and may scar but do not require surgery. Deep partial-thickness (second-degree) burns (formerly known as 2B burns) are less painful due to the partial destruction of the pain receptors, which are drier, require surgery, and will scar. A full-thickness (third-degree) burn extends through the full dermis and is not typically painful owing to damage to the nerve endings and requires protection from becoming infected and, unless minimal, surgical management.

Burns Market Key Facts

• The market size for Burns injury was USD 827 million in 2021 in the United States.

• The Burns market size in the EU5 was USD 491 million in 2021. EU5 accounted for nearly 32% of the total 7MM market size. 

• Among the EU5 countries, the United Kingdom holds the highest market size of USD 160 million, followed by France (USD 103 million) and Germany (USD 85 million). Spain holds the least market size of USD 71 million among the EU5 countries in 2021.

• The Burns market size in Japan was USD 222 million in 2021. Japan accounted for 14% of the total 7MM market size.

• In 2021, the total incident population of burn injuries that required medical treatment in seven major markets was reported to be 1,864,208.

• The estimates suggest the United States had the highest incident population of burn injuries that required medical treatment, with 661,900 cases in 2021.

• According to our analysis, after fire/flame (41%), scald was the foremost contributing cause of burn injuries in the US, occupying 31.4% of total incident cases of treatment-taking burn injuries.

• According to our assessments for the United States, the estimated cases of hospitalized burn patients in 2021 were 76,383.

• Japan had 328,255 incident cases of burn injuries requiring medical treatment in 2021, the second-highest of all other countries in 7MM after the US.

Burns Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Burns pipeline therapies. It also thoroughly assesses the Burns market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete details of the market trend for each marketed Burns drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Burns Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted Burns epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Burns epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the Burns Epidemiology, Segmented as –

• Incident Cases of Burn Patients Requiring Treatment

• Gender-specific Incident Cases of Treated Burn Injuries

• Etiology-specific Incident Cases of Treated Burn Injuries

• Severity-specific Incident Cases of Treated Burn Injuries

• Incident Cases of Hospitalized Burn Patients Scenario

Burns Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Burns market or expected to be launched during the study period. The analysis covers the Burns market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Burns drugs based on their sale and market share.

The report also covers the Burns pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Burns companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Burns Market Will Evolve and Grow by 2032 @ 

https://www.delveinsight.com/sample-request/burns-market

Burns Therapeutics Analysis

In the current market scenario, the standard treatment for skin burns involves medications, wound dressings, therapy, and surgery. The treatment goals are to control pain, remove dead tissue, prevent infection, reduce scarring risk, and regain function. The treatment depends on the severity of the burn.

Medical treatment includes water-based treatments (Ultrasound mist therapy to clean and stimulate the wound tissue), fluids to prevent dehydration (intravenous (IV) fluids to prevent dehydration and organ failure), pain and anxiety medications (morphine and anti-anxiety medications), creams and ointments (bacitracin and silver sulfadiazine), dressings (wound dressings), and common topical antimicrobials such as silver sulfadiazine (SSD), cerium plus SSD, silver nitrate, mafenide, bacitracin, and Xeroform.

Additionally, because children have limited glycogen stores, they should be given weight-based maintenance intravenous fluid in the form of 5% dextrose in 4.5% normal saline in addition to burning resuscitation fluid. Elderly patients have a unique acute phase response after burn injury, characterized by decreased organ perfusion and oxygenation.

To further improve the treatment outlook, several major pharma and biotech companies are developing therapies for Burns. Currently, NeoMatrix Therapeutics is leading the therapeutics market with its Burns drug candidates in the most advanced stage of clinical development.

Burns Companies Actively Working in the Therapeutics Market Include

MediWound Germany GmbH, Kaken Pharmaceutical Co., Ltd., Kerecis, Mallinckrodt Pharmaceuticals, Avita Medical, Vericel Corporation, KeraNetics, Integra LifeSciences Corporation, PolyNovo, Medline Industries, Anika Therapeutics, Inc., ACell, Inc., Amryt Pharma, CUTISS AG, Skingenix, RenovaCare, and others.

Emerging and Marketed Burns Therapies Covered in the Report Include:

• NexoBrid/KMW-1: MediWound Germany GmbH/Kaken Pharmaceutical Co., Ltd.

• Kerecis Omega3: Kerecis

• StrataGraft: Mallinckrodt Pharmaceuticals

• MW-III: Skingenix

• EHSG-KF (denovoSkin): CUTISS AG

And Many Others

Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @

https://www.delveinsight.com/sample-request/burns-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Burns Competitive Intelligence Analysis

4. Burns Market Overview at a Glance

5. Burns Disease Background and Overview

6. Burns Patient Journey

7. Burns Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Burns Treatment Algorithm, Current Treatment, and Medical Practices

9. Burns Unmet Needs

10. Key Endpoints of Burns Treatment

11. Burns Marketed Therapies

12. Burns Emerging Drugs and Latest Therapeutic Advances

13. Burns Seven Major Market Analysis

14. Attribute Analysis

15. Burns Market Outlook (In US, EU5, and Japan)

16. Burns Companies Active in the Market

17. Burns Access and Reimbursement Overview

18. KOL Views on the Burns Market

19. Burns Market Drivers

20. Burns Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Request the Sample PDF to Learn More About the Key Offerings of the Report @

https://www.delveinsight.com/sample-request/burns-market

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports by DelveInsight

Campylobacter Infections Market

“Campylobacter Infections Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Campylobacter Infections market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Campylobacter Infections market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/medical-devices

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Burns Market Set to Experience Unprecedented Growth During the Forecast Period (2023-32) – Asserts DelveInsight | MediWound, Kaken Pharma, Kerecis, Mallinckrodt, Avita Medical, KeraNetics, PolyNovo

“Delveinsight Business Research LLP”

DelveInsight’s “Thrombocytopenia Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Thrombocytopenia market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Thrombocytopenia drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Thrombocytopenia treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Thrombocytopenia: An Overview

Thrombocytopenia is a medical condition in which the platelet count in the blood falls (<150,000/µL of circulating blood) below the normal value. The etiology of thrombocytopenia is vast as many conditions may lead to low platelet count in the blood. The most common etiologies are heparin-induced thrombocytopenia, chemotherapy-induced thrombocytopenia, thrombocytopenia associated with chronic liver disease, immune thrombocytopenia (ITP), and thrombotic thrombocytopenic purpura (TTP).

Thrombocytopenia often improves when its underlying cause is treated. People who inherit the condition do not usually need treatment. If a reaction to a medicine is causing a low platelet count, the doctor may prescribe another medicine. Most people recover after the initial medicine has been stopped. For heparin-induced thrombocytopenia (HIT), stopping the heparin is not enough. Often, the patients need another medicine to prevent blood clotting. If the immune system is causing a low platelet count, the doctor may prescribe medicines to suppress the immune system.

Thrombocytopenia can result from decreased platelet production, increased platelet consumption, or sequestration. A systematic approach should be used to evaluate incidental thrombocytopenia. Physicians should inquire about easy bruising or petechiae, melena, rashes, fevers, and bleeding during the patient’s history. They also should inquire about medication use, immunizations, recent travel, transfusion history, family history, and medical history. A history of acute and chronic alcohol use should be obtained. Any recent hospitalization or heparin exposure should raise the possibility of heparin-induced thrombocytopenia.

Thrombocytopenia Market Key Facts

• In 2021, the US has the largest Thrombocytopenia market size of USD 2,447 million among the 7MM countries.

• Among the EU-5 countries, Germany had the highest Thrombocytopenia market size in 2021, i.e., USD 431 million. The lowest Thrombocytopenia market size was estimated in France, with USD 242 million in 2021.

• In Japan, the Thrombocytopenia market size was observed to be USD 328 million in 2021.

• In 2021, the total cases of Thrombocytopenia in the 7MM countries were 2,608,095, and these cases are anticipated to increase during the study period. The US accounted for 1,045,247 cases of Thrombocytopenia in 2021.

• Among the European countries, Germany had the highest number of cases of Thrombocytopenia in 2021, i.e., 453,441 cases, followed by the UK which had 269,422 cases in 2021. On the other hand, Italy had the lowest number of cases of Thrombocytopenia, i.e. 127,166 cases in 2021.

• The highest cases of TTP were seen in the US, which accounted for 6,002 cases in 2021.

• Japan, in 2021, accounted for 58,261 cases of Chemotherapy-induced Thrombocytopenia, which is expected to increase during the study period.

• The maximum number of cases of Heparin-induced Thrombocytopenia in 2021 was recorded in Germany out of all the EU-5 countries, and Spain accounted for the least number of cases.

Thrombocytopenia Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Thrombocytopenia pipeline therapies. It also thoroughly assesses the Thrombocytopenia market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete details of the market trend for each marketed Thrombocytopenia drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Thrombocytopenia Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted Thrombocytopenia epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Thrombocytopenia epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the Thrombocytopenia Epidemiology, Segmented as –

• Total Cases of Thrombocytopenic Purpura (TTP)

• Total Cases of Immune Thrombocytopenia (ITP)

• Total Cases of Thrombocytopenia in Chronic Liver Disease

• Total Cases of Chemotherapy-induced Thrombocytopenia

• Total Number of Cases of Heparin-induced Thrombocytopenia

• Total Cases of Thrombocytopenia Scenario

Thrombocytopenia Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Thrombocytopenia market or expected to be launched during the study period. The analysis covers the Thrombocytopenia market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Thrombocytopenia drugs based on their sale and market share.

The report also covers the Thrombocytopenia pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Thrombocytopenia companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Thrombocytopenia Market Will Evolve and Grow by 2032 @ 

https://www.delveinsight.com/sample-request/thrombocytopenia-market

Thrombocytopenia Therapeutics Analysis

Corticosteroids are the most commonly used first-line therapy for ITP. Treatment is initiated with prednisolone or prednisone (1–2 mg/kg per day, p.o., single or divided doses). In general, corticosteroids are initially effective. A study comparing high- and low-dose corticosteroids in adult patients found that low-dose therapy was initially more effective, although long-term effects have not been determined.

The approved therapies for treating thrombocytopenia in the US include MULPLETA, DOPTELET, TAVALISSE, PROMACTA, NPLATE, CABLIVI, GAMMAPLEX, OCTAGAM, RHOPHYLAC, and PRIVIGEN. These therapies are approved for various patient groups; for example, MULPLETA and DOPTELET are approved for thrombocytopenia in chronic liver disease, PROMACTA is approved for chronic immune (idiopathic) thrombocytopenic purpura (ITP).

The approved therapies in the EU include MULPLETA/MULPLEO (lusutrombopag), DOPTELET (avatrombopag), TAVALISSE/TAVLESSE (fostamatinib), PROMACTA/REVOLADE (eltrombopag), NPLATE/ROMIPLATE (romiplostim), and CABLIVI (caplacizumabum).

OCTAGAM, RHOPHYLAC, and PRIVIGEN are the immunoglobulins approved in the EU to treat immune thrombocytopenic purpura.

The approved medications in Japan for the treatment of thrombocytopenia include various etiologies like MULPLETA/ MULPLEO (lusutrombopag), PROMACTA/REVOLADE (eltrombopag), NPLATE/ROMIPLATE (romiplostim), and RITUXAN (rituximab).

To further improve the treatment scenario, several major pharma and biotech companies are developing therapies for Thrombocytopenia. Currently, Argenx is leading the therapeutics market with its Thrombocytopenia drug candidates in the most advanced stage of clinical development.

Thrombocytopenia Companies Actively Working in the Therapeutics Market Include

Sanofi, Principia Biopharma, Baxalta, Takeda, Argenx, Millennium Pharmaceuticals, Biotest, GC Pharma, Genosco (Subsidiary of Oscotec), Rigel Pharmaceuticals, Kissei Pharmaceutical, Shionogi & Co., Ltd, Amgen, Novartis, Zenyaku Kogyo, and others.

Emerging and Marketed Thrombocytopenia Therapies Covered in the Report Include:

• Efgartigimod alfa – Argenx

• Rozanolixizumab: UCB

• Cevidoplenib: Genosco

• Sovleplenib: HUTCHMED

• TAK-755: Baxalta/Takeda

• Rilzabrutinib: Sanofi/Principia Biopharma

And Many More

Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @

https://www.delveinsight.com/sample-request/thrombocytopenia-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Thrombocytopenia Competitive Intelligence Analysis

4. Thrombocytopenia Market Overview at a Glance

5. Thrombocytopenia Disease Background and Overview

6. Thrombocytopenia Patient Journey

7. Thrombocytopenia Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Thrombocytopenia Treatment Algorithm, Current Treatment, and Medical Practices

9. Thrombocytopenia Unmet Needs

10. Key Endpoints of Thrombocytopenia Treatment

11. Thrombocytopenia Marketed Therapies

12. Thrombocytopenia Emerging Drugs and Latest Therapeutic Advances

13. Thrombocytopenia Seven Major Market Analysis

14. Attribute Analysis

15. Thrombocytopenia Market Outlook (In US, EU5, and Japan)

16. Thrombocytopenia Companies Active in the Market

17. Thrombocytopenia Access and Reimbursement Overview

18. KOL Views on the Thrombocytopenia Market

19. Thrombocytopenia Market Drivers

20. Thrombocytopenia Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Request the Sample PDF to Learn More About the Key Offerings of the Report @

https://www.delveinsight.com/sample-request/thrombocytopenia-market

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports by DelveInsight

Juvenile Idiopathic Arthritis (JIA) Market

“Juvenile Idiopathic Arthritis (JIA) Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Juvenile Idiopathic Arthritis market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Juvenile Idiopathic Arthritis market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/market-research

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Thrombocytopenia Market to Expand at a Significant Growth Rate During the Forecast Period (2023-32) – Asserts DelveInsight | Sanofi, Baxalta, Takeda, Argenx, GC Pharma, Genosco, Amgen, Novartis